AU2020363903A1 - Prodrugs of myeloperoxidase inhibitors - Google Patents

Prodrugs of myeloperoxidase inhibitors Download PDF

Info

Publication number
AU2020363903A1
AU2020363903A1 AU2020363903A AU2020363903A AU2020363903A1 AU 2020363903 A1 AU2020363903 A1 AU 2020363903A1 AU 2020363903 A AU2020363903 A AU 2020363903A AU 2020363903 A AU2020363903 A AU 2020363903A AU 2020363903 A1 AU2020363903 A1 AU 2020363903A1
Authority
AU
Australia
Prior art keywords
group
substituted
unsubstituted
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020363903A
Other languages
English (en)
Inventor
Gene M. Dubowchik
Joseph Theodore Lundquist Iv
Melody A. Mcwherter
Jeffrey C. Pelletier
Allen B. Reitz
Eric Strobel
Yan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of AU2020363903A1 publication Critical patent/AU2020363903A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2020363903A 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors Abandoned AU2020363903A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913417P 2019-10-10 2019-10-10
US62/913,417 2019-10-10
PCT/US2020/054896 WO2021072140A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Publications (1)

Publication Number Publication Date
AU2020363903A1 true AU2020363903A1 (en) 2022-03-24

Family

ID=75438074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020363903A Abandoned AU2020363903A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Country Status (11)

Country Link
US (1) US20240067651A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041735A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022552834A (cg-RX-API-DMAC7.html)
KR (1) KR20220080133A (cg-RX-API-DMAC7.html)
CN (1) CN114945573A (cg-RX-API-DMAC7.html)
AU (1) AU2020363903A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006381A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157260A1 (cg-RX-API-DMAC7.html)
IL (1) IL291891A (cg-RX-API-DMAC7.html)
MX (1) MX2022004203A (cg-RX-API-DMAC7.html)
WO (1) WO2021072140A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010902A (es) * 2020-03-05 2022-10-07 Biohaven Therapeutics Ltd Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012797A1 (en) * 1989-04-19 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sulfer-containing xanthine derivatives as adenosin antagonists
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
SG11202000086PA (en) * 2017-07-17 2020-02-27 Astrazeneca Ab Mpo inhibitors for use in medicine

Also Published As

Publication number Publication date
JP2022552834A (ja) 2022-12-20
MX2022004203A (es) 2022-07-04
CA3157260A1 (en) 2021-04-15
EP4041735A4 (en) 2023-11-22
IL291891A (en) 2022-06-01
KR20220080133A (ko) 2022-06-14
CN114945573A (zh) 2022-08-26
WO2021072140A1 (en) 2021-04-15
US20240067651A1 (en) 2024-02-29
BR112022006381A2 (pt) 2022-06-28
EP4041735A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
ES2974287T3 (es) Derivado de anillo fusionado que tiene actividad inhibidora de MGAT-2
JP2022174114A (ja) Alkタンパク質分解剤及びそれらの癌療法における使用
CN111787916B (zh) 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂
US12421276B2 (en) Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues
EP4570792A1 (en) Compound based on isoindoline-substituted glutarimide backbone and use thereof
EP2518067B1 (fr) Dérives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide et leurs applications en thérapeutique comme antagonistes de p2y12.
TWI531573B (zh) 新穎反轉模擬物之化合物及其用途
EP2387315A1 (en) IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
JP5892620B2 (ja) ピラゾール誘導体
WO2021072140A1 (en) Prodrugs of myeloperoxidase inhibitors
WO2023284703A1 (zh) 基于布鲁顿酪氨酸激酶配体设计的蛋白降解化合物及其应用
US12358925B2 (en) Targeted ubiquitination degradation BRD4 protein compound, preparation method therefor and application thereof
CN117659016A (zh) 细胞周期蛋白调节剂
EP2523552B1 (en) Pyrazolo[1,5-a]pyrimidines as mark inhibitors
US9675584B2 (en) Substituted indoles for the inhibition of PASK
US20240408106A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
CN115745963B (zh) 基于nampt靶蛋白的蛋白降解化合物及其应用
KR20130115100A (ko) 헥사히드로피롤로[3,4-b]피롤유도체, 그의 제조방법 및 그의 용도
WO2023220722A2 (en) Pak1 degraders and methods of use thereof
US20170320910A1 (en) Inhibitors for inhibiting tumor metastasis
WO2023235719A2 (en) Stereoselective allosteric inhibitors of sarm1
US20260116923A1 (en) Cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders
CN113087724B (zh) 异噻唑并嘧啶酮类化合物,包含其的药物组合物及其用途
CN121627686A (zh) 多环杂芳烃类glp-1受体激动剂

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period